Article
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
All News
Article
Arthritis & Rheumatology reports that treatment trends in juvenile idiopathic arthritis (JIA) in the last two decades finds rising use of newer biologic and targeted synthetic DMARDs coupled with a decline in conventional DMARD use.
Article
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
Article
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
Article
A phase 2 trial of EP-104IAR (long-acting, fluticasone propionate) has shown 14 weeks of clinically meaningful pain relief in knee osteoarthritis (OA).
Dr. John Cush
Tweet
Early bird pricing ends 10/31. Secure your seat for RheumNow Live today!
https://t.co/TBNLxfBbEF https://t.co/6OLHEXCvUw
Dr. John Cush
Tweet
Potential OA Treatment - Chemokine CCL17 Inhibition
Patients with osteoarthritis (OA) of the knee receiving an investigational chemokine inhibitor showed some improvements in pain and disability, said researchers with the drug's developer.
https://t.co/MYYBBIIuDA https://t.co/1AfbxCuGIq
Dr. John Cush
Tweet
Heritability of asymptomatic ANA positivity is 25%. Asymptomatic ANA positive individuals did not exhibit increased cumulative genetic risk for lupus compared to ANA negative individuals. Genetic study of 1,955 asymptomatic ANA+ v 3,634 asymptomatic ANAnegs.… https://t.co/P0MmFfG7NV https://t.co/KnlyNPKG4s
Dr. John Cush
Tweet
Long-term Tofacitinib in Juvenile Idiopathic Arthritis
The long-term safety and efficacy of tofacitinib in patients with juvenile idiopathic arthritis (JIA) has been established in an ongoing long term extension (LTE) study.
https://t.co/IKHM6z8iMB https://t.co/O6ig1lTQR4
Dr. John Cush
Tweet
Relapse of idiopathic inflammatory myopathies (IIMs) was seen 65/105 (62%) pts. Higher risk seen w/ ANA positivity (HR 1.13), w/ + histopathology on muscle Bx (HR 1.69), & immunosuppressants use before relapse (HR 0.50). https://t.co/tr0OdvOAPK https://t.co/H3t3u1mDtd
Dr. John Cush
Tweet
Predictors of Adverse Pregnancy Outcomes in Lupus
A large metanalysis of systemic lupus erythematosus (SLE) patients and pregnancy outcomes suggests that adverse pregnancy outcomes are more likely in those with lupus nephritis, chronic hypertension, SLE disease activity before… https://t.co/31dqOyD3ZR https://t.co/L9LMn2CPYS
Dr. John Cush
Tweet
2 yr results from the PRAIRI study - 78 at-risk (for RA) pts Rx w/ placebo or 1000 mg IV RTX + I00 mg methylprednisolone (MP). While 1 yr result showed brief delay in RA development, at 2 yrs there was no benefit for QOL or RA development https://t.co/1CzEQn5zL4 https://t.co/Wvr2kWvDC5
Dr. John Cush
Tweet
Retrospective study compared IV methylprednisolone (IVMP) to oral glucocorticoids (GC) Rx in 419 #GCA pts (>90% vision Sx). 26% Rx w/ IVMP was not superior at survival or visual ac uity than GC, but IVMP was assoc w/ signif more diabetes @1 yr (OR 2.59) https://t.co/pRBA18Fzyw https://t.co/z6Sw5LTtGq
Dr. John Cush
Tweet
Anxiety and Depression Rising in Rheumatoid Arthritis
A Mayo Clinic study shows that over three decades, anxiety and depression have become more common in individuals with rheumatoid arthritis (RA).
https://t.co/sWawAgDgyS https://t.co/dVTb7QMFNj
Dr Ai Lyn Tan
Tweet
#VEXAS can present as atypical &/or refractory #ANCA-associated #vasculitis
Consider possibility of VEXAS in cases of AAV
▶️Refractory to multiple treatment
▶️Atypical kidney biopsy
👉🏽https://t.co/1Vewb5n5vZ
via @RheumJnl https://t.co/FLov5xaQAA
Dr. John Cush
Tweet
Biomarker substudy of #SLE Rx w/ low dose IL-2 Rx in 342 pts (40% responders). SRI-4 predicted by rash, proteinuria, uRBC, %CD4 T cells, C3 (AUC 0.9330; however renal markers did not correlate with achieving LLDAS. https://t.co/pDgwegbU6t https://t.co/72w4gNAiWt
Dr. John Cush
Tweet
In PsA poor Rx adherencecontributes to suboptimal outcomes. 685 PsA started b/tsDMARDs 2018-2019 w/ persistence of 263 days (49% persistent for 1 yr). Similar adherence betw ADA & its biosimilar. https://t.co/QVbEVvYz7y https://t.co/1Te22NIUGT
Dr. John Cush
Tweet
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.
https://t.co/cH4s99Fzka https://t.co/kNcUqahmeS
Dr. John Cush
Tweet
Retrospective population study of 383 #AS women who were pregnant (3.8/100,000) compared to controls. AS-Preg pts more likely to be older; White, w/ higher incomes, MORE thyroid Dz, Pregs, C-Sections, gestational DM, placenta previa, more neonatal SGA, IUFD… https://t.co/pgsmKgljwx https://t.co/IMJ8CTrqhY
Dr. John Cush
Tweet
Study of AutoAbs in 141 pts w/ systemic sclerosis overlap syndrome (SSc OS). Most common Abs: Ro-52, centromere (ACA) & anti-Scl-70. Scl-70 was assoc w/ ILD & SSc renal crisis (SRC); while ACA is protective factor of ILD. SRC & pulm HTN assoc w/ incr mortality… https://t.co/sqQhIlZjdB https://t.co/noyaFbd3Z8
